紫杉醇联合奥沙利铂化疗方案对宫颈癌患者血清FGFR4、Spondin-2水平的影响  

Effect of paclitaxel combined with oxaliplatin chemotherapy on serum FGFR4 and Spondin-2 levels in patients with cervical cancer

作　　者：张鹏[1] 杨海霞[1] ZHANG Peng;YANG Hai-xia(Department of Pharmacy,Suining City Central Hospital,Suining Sichuan 629000,China)

机构地区：[1]遂宁市中心医院药剂科,四川遂宁629000

出　　处：《临床和实验医学杂志》2022年第15期1623-1626,共4页Journal of Clinical and Experimental Medicine

基　　金：四川省科技厅项目(编号:2014JY0044)。

摘　　要：目的 探讨紫杉醇联合奥沙利铂化疗方案对宫颈癌患者血清成纤维细胞生长因子受体4(FGFR4)、脊椎蛋白2(Spondin-2)水平的影响。方法 前瞻性选取2017年3月至2018年12月遂宁市中心医院收治的87例宫颈癌患者作为研究对象,按照随机数字表法将其分为观察组(n=44)和对照组(n=43),其中观察组实施紫杉醇联合奥沙利铂进行化疗,对照组实施紫杉醇化疗。比较治疗后两组患者血清FGFR4、Spondin-2水平、临床疗效、不良反应。结果治疗后,两组患者血清FGFR4、Spondin-2水平均较治疗前下降,且观察组血清FGFR4、Spondin-2水平为(126.53±46.39) pg/mL、(13.52±3.58)μg/L,均低于对照组[(154.68±53.09) pg/mL、(15.62±3.41)μg/L],差异均有统计学意义(P <0.05)。治疗后,观察组患者临床总有效率为95.45%,高于对照组(74.41%),差异有统计学意义(P <0.05)。观察组不良反应总发生率为6.81%,低于对照组(30.23%),差异有统计学意义(P <0.05)。结论 紫杉醇联合奥沙利铂化疗方案能有效降低宫颈癌患者血清FGFR4、Spondin-2表达水平,疾病控制效果好,降低了不良反应发生率,值得临床推广使用。Objective To investigate the effect of paclitaxel combined with oxaliplatin chemotherapy on serum fibroblast growth factor receptor 4(FGFR4)and spondin-2 levels in patients with cervical cancer.Methods Eighty-seven patients with cervical cancer admitted to Suining City Central Hospital from March 2017 to December 2018 were prospectively selected and divided into an observation group(n=44)and a control group(n=43)according to a random number table.The observation group was treated with paclitaxel combined with oxaliplatin chemotherapy,while the control group was treated with paclitaxel chemotherapy.Serum FGFR4 and Spondin-2 levels,clinical efficacy,and adverse reactions were compared between the two groups after treatment.Results After treatment,the levels of serum FGFR4 and Spondin-2 in the two groups were lower than those before treatment,and the levels of serum FGFR4 and Spondin-2 in the observation group were(126.53±46.39)pg/mL,(13.52±3.58)μg/L,which were lower than those in the control group[(154.68±53.09)pg/mL,(15.62±3.41)μg/L],the differences were statistically significant(P<0.05).After treatment,the total clinical effective rate in the observation group was 95.45%,which was higher than that in the control group(74.41%),and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 6.81%,which was lower than that in the control group(30.23%),and the difference was statistically significant(P<0.05).Conclusion Paclitaxel combined with oxaliplatin chemotherapy can effectively reduce the serum expression levels of FGFR4 and Spondin-2 in patients with cervical cancer,with good disease control effect,which reduces the incidence of adverse reactions and has high safety.It is worthy of being widely popularized in the clinical application.

关 键 词：宫颈癌 紫杉醇 奥沙利铂 化疗 血清成纤维细胞生长因子受体4 脊椎蛋白2 

分 类 号：R737.33[医药卫生—肿瘤]